Drug Type CAR-T |
Synonyms CHT-101 |
Target |
Mechanism CD70 inhibitors(CD70 antigen inhibitors), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | - | 22 Apr 2024 | |
CD70 positive Neoplasms | Phase 1 | - | 22 Apr 2024 | |
Nasopharyngeal Carcinoma | Phase 1 | - | 22 Apr 2024 | |
Neoplasm Metastasis | Phase 1 | - | 22 Apr 2024 | |
Ovarian Cancer | Phase 1 | - | 22 Apr 2024 | |
Renal Cell Carcinoma | Phase 1 | - | 22 Apr 2024 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | - | 22 Apr 2024 | |
Uterine Cervical Cancer | Phase 1 | - | 22 Apr 2024 | |
Acute Myeloid Leukemia | Phase 1 | CN | 18 Nov 2021 | |
Acute Myeloid Leukemia | Phase 1 | CN | 18 Nov 2021 |